13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001346824
Total reported value
$11.5B
$11.5B
78 檔
25.8%
According to the latest 13F quarterly dataset, Ra Capital Management, L.p. managed an equity portfolio of $11.5B at the end of Q2 2024, spanning 78 distinct U.S. exchange-listed positions.
In Q2 2024, Ra Capital Management, L.p. displayed an active expansion posture, initiating 6 new positions and adding to 16 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Stock-Other | 18.23% | -24.92% | EXIT | |
| 2 | PCVX | Vaxcyte Inc | Stock-Other | 8.19% | -1.27% | — | |
| 3 | JANX | Janux Therapeutics Inc | Stock-Other | 5.08% | -0.16% | — | |
| 4 | LEGN | Legend Biotech Corp-adr | Stock-Other | 4.40% | — | +9.41% | |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.30% | +0.29% | +14.15% | |
| 6 | BIIB | Biogen Inc | Stock-Healthcare | 3.01% | — | +32.59% | |
| 7 | CLYM | Climb Bio Inc | Stock-Other | 2.95% | +0.46% | +138.91% | |
| 8 | RXST | Rxsight Inc | Stock-Other | 2.94% | — | +7.32% | |
| 9 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.92% | — | +64.54% | |
| 10 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.82% | — | +22.09% | |
| 11 | GERN | Geron CORP | Stock-Other | 2.59% | -0.53% | — | |
| 12 | PEPG | Pepgen Inc | Stock-Other | 2.26% | -0.07% | — | |
| 13 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.20% | -1.56% | — | |
| 14 | EVH | Evolent Health Inc - A | Stock-Other | 2.15% | — | +48.44% | |
| 15 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.12% | -0.52% | — | |
| 16 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 2.05% | -0.43% | +2.54% | |
| 17 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 1.53% | — | — | |
| 18 | ETNBGBP | 89bio Inc | Stock-Other | 1.50% | — | +11.03% | |
| 19 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.46% | — | +20.81% | |
| 20 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.43% | — | +0.79% | |
| 21 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 1.42% | +0.08% | +0.92% | |
| 22 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.22% | -0.16% | — | |
| 23 | WVE | Wave Life Sciences Ltd. | Stock-Other | 1.20% | -0.71% | — | |
| 24 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 1.18% | — | — | |
| 25 | ACLXGBX | Arcellx Inc | Stock-Other | 1.17% | — | — | |
| 26 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.06% | — | — | |
| 27 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.02% | — | -0.81% | |
| 28 | GHRS | GH Research PLC | Stock-Other | 1.02% | +0.64% | +5.60% | |
| 29 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.99% | — | +25.58% | |
| 30 | LENZ | Lenz Therapeutics Inc | Stock-Other | 0.96% | -0.20% | — | |
| 31 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.95% | -0.49% | EXIT | |
| 32 | NKTX | Nkarta Inc | Stock-Other | 0.84% | +0.03% | — | |
| 33 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.80% | -2.32% | EXIT | |
| 34 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.75% | -0.41% | — | |
| 35 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.69% | — | -20.37% | |
| 36 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.68% | — | — | |
| 37 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.68% | -1.28% | EXIT | |
| 38 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.66% | — | — | |
| 39 | ACRV | Acrivon Therapeutics Inc | Stock-Other | 0.64% | +0.07% | +73.38% | |
| 40 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.61% | — | +14.29% | |
| 41 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.60% | — | +181.63% | |
| 42 | CGON | Cg Oncology Inc | Stock-Other | 0.58% | — | — | |
| 43 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.58% | — | — | |
| 44 | ABOS | Acumen Pharmaceuticals Inc | Stock-Other | 0.48% | -0.03% | — | |
| 45 | TRML | Tourmaline Bio Inc | Stock-Other | 0.43% | — | — | |
| 46 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.35% | — | — | |
| 47 | SLDB | Solid Biosciences Inc | Stock-Other | 0.32% | +0.33% | — | |
| 48 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.32% | +0.27% | — | |
| 49 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.31% | — | +32.45% | |
| 50 | VOR | Vor Biopharma Inc. | Stock-Other | 0.30% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CLYM | Climb Bio Inc | +2.5% | +138.91% | Add |
| 2 | RNAGBP | Avidity Biosciences Inc | +1.9% | +64.54% | Add |
| 3 | RXRX | Recursion Pharmaceuticals-a | +1.5% | NEW | New buy |
| 4 | ACLXGBX | Arcellx Inc | +1.2% | NEW | New buy |
| 5 | DYN | Dyne Therapeutics Inc | +1% | +22.09% | Add |
| 6 | PCVX | Vaxcyte Inc | +1% | — | Unchanged |
| 7 | BIIB | Biogen Inc | +1% | +32.59% | Add |
| 8 | RXST | Rxsight Inc | +0.7% | +7.32% | Add |
| 9 | JANX | Janux Therapeutics Inc | +0.7% | — | Unchanged |
| 10 | GERN | Geron CORP | +0.6% | — | Unchanged |
| 11 | CGON | Cg Oncology Inc | +0.6% | NEW | New buy |
| 12 | TRML | Tourmaline Bio Inc | +0.4% | NEW | New buy |
| 13 | BCYC | Bicycle Therapeutics Plc-adr | +0.3% | +181.63% | Add |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | +0.3% | +14.15% | Add |
| 15 | ✓ | Longboard Pharmaceuticals In | +0.3% | — | Unchanged |
| 16 | PEPG | Pepgen Inc | +0.3% | — | Unchanged |
| 17 | ACRV | Acrivon Therapeutics Inc | +0.2% | +73.38% | Add |
| 18 | NRIX | Nurix Therapeutics Inc | +0.2% | NEW | New buy |
| 19 | INSM | Insmed Inc | +0.2% | NEW | New buy |
| 20 | ELVN | Enliven Therapeutics Inc | +0.2% | — | Unchanged |
| 21 | CYBNEUR | Cybin Inc | -0.2% | -24.31% | Trim |
| 22 | MGX | Metagenomi Therapeutics Inc | -0.2% | -15.29% | Trim |
| 23 | CATBUSD | Astria Therapeutics Inc | -0.2% | +14.29% | Add |
| 24 | SPRY | Ars Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 25 | CCCC | C4 Therapeutics Inc | -0.2% | — | Unchanged |
| 26 | DAWNGBX | Day One Biopharmaceuticals I | -0.2% | +0.79% | Add |
| 27 | BDTX | Black Diamond Therapeutics I | -0.2% | EXIT | Sold out |
| 28 | WVE | Wave Life Sciences Ltd. | -0.2% | — | Unchanged |
| 29 | LENZ | Lenz Therapeutics Inc | -0.2% | — | Unchanged |
| 30 | EYPT | Eyepoint Inc | -0.3% | EXIT | Sold out |
| 31 | EVH | Evolent Health Inc - A | -0.3% | +48.44% | Add |
| 32 | VXRT | Vaxart Inc | -0.3% | EXIT | Sold out |
| 33 | MGNX | Macrogenics Inc | -0.3% | — | Unchanged |
| 34 | BOLD | Boundless Bio Inc | -0.3% | — | Unchanged |
| 35 | ABOS | Acumen Pharmaceuticals Inc | -0.3% | — | Unchanged |
| 36 | HOWL | Werewolf Therapeutics Inc | -0.3% | — | Unchanged |
| 37 | NAMS | NewAmsterdam Pharma Company N.V. | -0.3% | +2.54% | Add |
| 38 | VOR | Vor Biopharma Inc. | -0.4% | — | Unchanged |
| 39 | ETNBGBP | 89bio Inc | -0.4% | +11.03% | Add |
| 40 | SLDB | Solid Biosciences Inc | -0.4% | — | Unchanged |
| 41 | FULC | Fulcrum Therapeutics Inc | -0.5% | — | Unchanged |
| 42 | LEGN | Legend Biotech Corp-adr | -0.5% | +9.41% | Add |
| 43 | CTKB | Cytek Biosciences Inc | -0.6% | EXIT | Sold out |
| 44 | FDMT | 4d Molecular Therapeutics In | -0.6% | +0.92% | Add |
| 45 | NKTX | Nkarta Inc | -0.7% | — | Unchanged |
| 46 | APGE | Apogee Therapeutics Inc | -0.7% | -0.81% | Trim |
| 47 | MDGL | Madrigal Pharmaceuticals Inc | -0.7% | EXIT | Sold out |
| 48 | INBXUSD | Inhibrx Inc | -1.2% | EXIT | Sold out |
| 49 | ASND | Ascendis Pharma A/S | -1.4% | — | Unchanged |
| 50 | ✓ | -2.9% | +11.23% | Add |
According to official SEC Form 13F filings, Ra Capital Management, L.p. reported a total U.S. public equity portfolio value of $11.5B across 78 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ASND, PCVX, JANX) accounted for 25.8% of total reported equity market value during Q2 2024.
Top New Position Initiated
RXRX
市值: $115.4M
Top Position Liquidated / Trimmed
INBXUSD
前期市值: $91.9M
During Q2 2024, Ra Capital Management, L.p.'s top holdings by market value included ASND (18.2%)、PCVX (8.2%)、JANX (5.1%). The largest single position, ASND, represented 18.2% of total portfolio value.
In Q2 2024, Ra Capital Management, L.p. made 31 total portfolio adjustments, initiating 6 new buys, adding to 16 positions, trimming 3 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.